Stiff Person Syndrome Patients Show Remarkable Mobility Gains With Kyverna's CAR T Cell Therapy

Kyverna Therapeutics (KYTX) has released pivotal Phase 2 clinical data demonstrating that its cel-based immunotherapy miv-cel delivers transformative outcomes in stiff person syndrome, a rare and severely disabling autoimmune neurological condition. The findings represent the first major advancement for this patient population, where no FDA-approved treatment options currently exist.

Understanding The Clinical Challenge

Stiff person syndrome is characterized by progressive muscle rigidity and involuntary spasms that progressively impair mobility and quality of life. The condition stems from autoimmune dysfunction, making it particularly challenging to treat with conventional therapies. Prior to this breakthrough, patients had limited options and faced the prospect of ongoing disability.

Miv-cel: Engineering A Cellular Solution

Miv-cel, previously designated KYV-101, represents a fully human autologous CD19-targeting cel therapy incorporating CD28 co-stimulation. The mechanism works by inducing comprehensive B-cell depletion and triggering immune system restoration. Theoretically, this single treatment can establish sustained, medication-free remission in autoimmune conditions—a paradigm shift from conventional management approaches.

KYSA-8 Trial: Impressive Clinical Efficacy

The KYSA-8 registrational Phase 2 study enrolled 26 adult patients with stiff person syndrome who had experienced inadequate responses to prior treatments. The trial’s primary endpoint assessed functional mobility using the timed 25-foot walk test at Week 16.

Results exceeded expectations:

• Patients achieved a median 46% improvement in walking ability, with 81% demonstrating clinically meaningful gains exceeding 20%
• Secondary efficacy measures showed consistent benefits across disability assessments, stiffness scoring, and ambulation capacity
• Among the 12 patients requiring mobility aids at baseline, approximately two-thirds no longer needed assistance by Week 16
• Critically, all participants remained free from immunosuppressive medications throughout the study, with zero patients requiring rescue therapy

Safety Profile Supports Further Development

The cel therapy demonstrated a favorable tolerability profile, with no serious cytokine release syndrome cases or immune effector cell-associated neurotoxicity reported. This safety foundation strengthens the development pathway for this therapeutic approach.

Regulatory Path Forward

Based on these compelling findings, Kyverna intends to submit a Biologics License Application (BLA) to the U.S. FDA during the first half of 2026, potentially positioning miv-cel as the first cel-based treatment for stiff person syndrome.

Expanding The Therapeutic Pipeline

Kyverna’s cel platform extends across multiple autoimmune indications. KYSA-6 evaluates KYV-101 in generalized myasthenia gravis, currently progressing through a registrational Phase 2/3 trial with interim Phase 2 data showing sustained disease score improvements and Phase 3 enrollment targeted for late 2025. Updated data are anticipated in 2026.

Additional applications in development include Phase 1 studies of KYV-101 in multiple sclerosis, demonstrating promising central nervous system penetration, and a Phase 1/2 program in treatment-refractory rheumatoid arthritis showing substantial reductions in disease biomarkers and clinical activity.

KYV-102, Kyverna’s next-generation cel product manufactured through proprietary whole blood rapid processing, aims to enhance accessibility by circumventing apheresis requirements and reducing manufacturing expenses. An Investigational New Drug (IND) application is expected in Q4 2025.

Financial Position And Market Performance

The company maintained a strong balance sheet as of September 30, 2025, with $171.1 million in cash and equivalents, augmented by an initial $25 million draw from a $150 million credit facility, extending operational runway into 2027.

The equity market has responded enthusiastically to the KYSA-8 data release. KYTX shares traded between $1.78 and $9.75 over the past 12 months but surged to a new 52-week high of $12.25 in pre-market trading, representing a 39.52% increase. This performance reflects investor recognition of the cel therapy’s clinical and commercial potential in addressing an underserved patient population with significant unmet medical needs.